Navigation Links
Yondelis(R) Sales Expanded by 70 Percent
Date:10/28/2010

MADRID, Oct. 28 /PRNewswire/ -- Group revenues totaled 120 million euro (approximately 167 million USD*) in the first nine months of 2010, i.e. an increase of 26.1 percent with respect to the same period last year (95.19 million euro or approximately 132.6 million USD).

Net sales in the Biopharmaceutical business amounted to 56.9 million euro or approximately 79.3 million USD (35.8 million euro or approximately 49.9 million USD in the first nine months of 2009), of which 51.8 million (approximately 72.1 million USD) correspond to Yondelis sales (30.4 million euro or approximately 42.3 million USD in 9M09). Genomica's sales totaled 5.1 million euro (approximately 7.1 million USD).

The Consumer chemicals division reported sales of 62.2 million euro or approximately 86.6 million USD (58.6 million euro or approximately 81.6 million USD in 9M09). This division accounted for 51.8 percent of total group revenues in the first nine months of 2010 (61.5 percent in 9M09).

The Group maintained positive EBITDA of 2.7 million euro (approximately 3.8 million USD) in 9M10, driven by steadily rising sales since the beginning of the year.

Net income attributable to the parent company improved 63 percent with respect to September 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.

For more information, Zeltia +34 91 444 4500

This note is also available at Zeltia's web site: www.zeltia.com

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3928.


'/>"/>
SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
2. Decision Resources Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
3. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
4. Assured Pharmacy Reports Same Store Sales for the Month of September 2010
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
6. Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010
7. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
8. Gerresheimer Reports Strong Earnings and Sales Growth
9. Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center
10. Health Strategies Group Introduces New One-Stop Suite of Intelligence Services for Optimizing Marketing and Sales Resources in the Institutional Channel
11. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... /PRNewswire/ - Demers Ambulances announces its first delivery in the state ... County Emergency Medical Services (EMS) consisting of four ... van. Quality Emergency Vehicles in Lecanto, FL ... This is the latest in Demers, ongoing expansion of sales.  ... Demers. --> Benoit LaFortune , Executive Vice President ...
(Date:2/12/2016)... Feb. 12, 2016   HeartWare International, Inc . ... and webcast to discuss its financial results for the ... Thursday, February 25, 2016 at 8:00 a.m. ET.  The ... the conference call and webcast.  On the conference call ... highlights from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Tech Outlook’s top Clinical Data Management Solution Providers list for its expertise in ... functional and domain expertise to serve the technology needs of global clients. DDi ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan ... The purpose of these scholarships is to encourage applicants to pursue a degree in ... within these two parishes. , “We have available jobs in St. Landry and ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
Breaking Medicine News(10 mins):